Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Apatinib mesilato combinato con regime IT per il trattamento del neuroblastoma pediatrico ricorrente o refrattario

5 novembre 2026 aggiornato da: Yizhuo Zhang, Sun Yat-sen University

Apatinib mesilato combinato con regime IT per il trattamento del neuroblastoma pediatrico ricorrente o refrattario: studio clinico multicentrico, a braccio singolo, di fase II.

The survival rate of recurrent and refractory neuroblastoma is low and the prognosis is poor. Apatinib mesylate is a highly selective small-molecule vasoendothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor. Apatinib mesylate has been shown to be safe and effective in recurrent or refractory pediatric neuroblastoma in Sun Yat-sen University Cancer Center. Apatinib mesylate combined with IT regimen is expected to further improve the efficacy and survival rate of recurrent or refractory neuroblastoma.

Panoramica dello studio

Stato

Completato

Condizioni

Descrizione dettagliata

The enrolled patients diagnosed with recurrent or refractory neuroblastoma received apatinib combined with IT regimen chemotherapy, including phase I and phase II stage. During the Phase I stage, apatinib was administered using a 3+3 dose escalation design with three dose cohorts. The IT regimen was maintained at fixed doses, with patients receiving up to 8 cycles of chemotherapy. The recommended Phase II dose (RP2D) was determined from the Phase I dose-escalation phase.

In the Phase II stage, the study included an apatinib combination therapy phase and an apatinib maintenance therapy phase. During the combination therapy phase, apatinib was administered at the RP2D in combination with the IT regimen (at fixed doses) for up to 8 cycles. In the maintenance therapy phase, apatinib was administered orally as a single agent at the RP2D until disease progression or intolerable toxicity occurred.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

111

Fase

  • Fase 2
  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Guangdong
      • Guangzhou, Guangdong, Cina
        • Sun Yat-sen University Cancer Center
      • Guangzhou, Guangdong, Cina
        • The First Affiliated Hospital of Guangdong Pharmaceutical University
      • Guangzhou, Guangdong, Cina
        • The Fifth Affiliated Hospital of Guangzhou Medical University
    • Hubei
      • Wuhan, Hubei, Cina
        • Wuhan Children's Hospital
    • Shandong
      • Jinan, Shandong, Cina
        • Jinan Children's Hospital

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

2 anni e precedenti (Bambino, Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Age ≥2 years (for patients enrolled in Phase 1, age <18 years); no gender restriction.
  2. Karnofsky Performance Status (KPS) score ≥50 for patients aged ≥16 years, or Lansky Performance Status (LPS) score ≥50 for patients aged <16 years (see Appendix 1).
  3. Estimated life expectancy of at least 12 weeks.
  4. Histologically confirmed diagnosis of neuroblastoma meeting clinical diagnostic criteria.
  5. Disease progression, recurrence, or treatment resistance (failure to achieve CR or PR following the most recent therapy) after first-line treatment.
  6. Measurable or evaluable disease (per INRC criteria; see Appendix 3; target lesions must not have received prior local treatment such as radiotherapy or cryotherapy).
  7. Complete recovery from all acute toxic effects of prior anticancer chemotherapy.
  8. Myelosuppressive chemotherapy: at least 21 days since the last myelosuppressive chemotherapy regimen (or 42 days if nitrosoureas were administered).
  9. Investigational agents or anticancer therapies other than chemotherapy: must not have been administered within 28 days prior to the planned initiation of the AIT regimen. Complete recovery from any clinically significant toxicity associated with such therapy must be confirmed.
  10. Hematopoietic growth factors: at least 14 days since the last administration of long-acting growth factors, or at least 3 days since the last administration of short-acting growth factors.
  11. Immunotherapy: at least 42 days since completion of any type of immunotherapy (excluding corticosteroids), such as immune checkpoint inhibitors or tumor vaccines.
  12. Radiotherapy (XRT): at least 14 days since localized palliative XRT (small-field irradiation); for other substantial bone marrow irradiation, including prior ¹³¹I-metaiodobenzylguanidine (¹³¹I-MIBG) therapy, a minimum interval of 42 days is required.
  13. Stem cell infusion without total body irradiation: no evidence of active graft-versus-host disease, and at least 56 days since transplantation or stem cell infusion.
  14. Laboratory tests during the screening period must meet the following criteria:

(1)Absolute neutrophil count (ANC) ≥1.5 × 10⁹/L (≥1.0 × 10⁹/L if bone marrow involvement is present) (2)Platelet count (PLT) ≥75 × 10⁹/L (≥50 × 10⁹/L if bone marrow involvement is present) (3)Total bilirubin ≤1.5 × upper limit of normal (ULN) (4)Serum creatinine ≤1.5 × ULN (5)Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ≤3 × ULN (may be ≤5 × ULN in the presence of liver metastases) 15.Ability to comply with outpatient treatment, laboratory monitoring, and required clinical visits during study participation.

16.Parents/legal guardians of pediatric or adolescent subjects must be capable of understanding, agreeing to, and signing the informed consent form (ICF) and applicable pediatric assent forms prior to the initiation of any protocol-related procedures. With parental/guardian consent, subjects must be capable of expressing assent (where applicable).

EXCLUSION CRITERIA:

Patients meeting any of the following criteria are ineligible for inclusion in this study:

  1. Symptomatic brain metastases (patients with brain metastases who have completed treatment within 21 days prior to enrolment and have stable symptoms may be enrolled, provided that cranial magnetic resonance imaging [MRI], computed tomography [CT], or venography confirms the absence of cerebral haemorrhage).
  2. Imaging (CT or MRI) demonstrating that the tumour lesion is located ≤5 mm from a major blood vessel, or that the tumour invades a local major blood vessel.
  3. Hypertension currently requiring treatment with two or more antihypertensive medications.
  4. Prior or concurrent clinically significant cardiovascular disease, including congenital heart disease, pericardial disease, history of heart failure, myocardial infarction, coronary artery disease, valvular heart disease, cardiomyopathy, or arrhythmias (including persistent atrial fibrillation, complete left bundle branch block, or frequent premature ventricular contractions); corrected QT interval (QTc) >480 ms; New York Heart Association (NYHA) Class III-IV cardiac dysfunction for patients aged >3 years or corresponding criteria for infantile cardiac function for patients aged ≤3 years (see Appendix 2); or echocardiography demonstrating left ventricular ejection fraction (LVEF) <50%.
  5. History of or concurrent interstitial lung disease.
  6. Abnormal coagulation function (international normalised ratio [INR] >1.5, prothrombin time [PT] >ULN + 4 seconds, or activated partial thromboplastin time [APTT] >1.5 × ULN), bleeding tendency, or ongoing thrombolytic or anticoagulant therapy.
  7. Haemoptysis of ≥2 teaspoons daily prior to enrolment.
  8. Clinically significant bleeding symptoms or clear bleeding tendency within the preceding 3 months, such as gastrointestinal bleeding, haemorrhagic haemorrhoids, haemorrhagic gastric ulcer, baseline faecal occult blood ≥++, or vasculitis.
  9. Arterial or venous thromboembolic events within 12 months prior to enrolment, including cerebrovascular accident (transient ischaemic attack, cerebral haemorrhage, or cerebral infarction), deep vein thrombosis, or pulmonary embolism.
  10. Known hereditary or acquired bleeding or thrombotic tendency (e.g., haemophilia, coagulation disorders, thrombocytopenia, or hypersplenism).
  11. Chronic non-healing wounds or fractures (excluding pathological fractures caused by tumours).
  12. Major surgical procedure, severe traumatic injury, fracture, or ulcer within 4 weeks prior to enrolment.
  13. Factors that significantly affect absorption of oral medications, such as inability to swallow, chronic diarrhoea, or intestinal obstruction.
  14. History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to enrolment.
  15. Urinalysis showing urinary protein ≥++, with confirmed 24-hour urinary protein excretion ≥1.0 g.
  16. Symptomatic serous effusion requiring intervention (including pleural effusion, ascites, and pericardial effusion). Note: Patients with asymptomatic serous effusion may be enrolled. Patients with symptomatic serous effusion who have received active symptomatic management (anticancer drugs are not permitted for the treatment of serous effusion) and are deemed eligible by the investigator may be enrolled.
  17. Active infection requiring antimicrobial therapy (e.g., antibacterial or antiviral agents, excluding anti-hepatitis B virus [HBV] therapy for chronic hepatitis B or antifungal therapy).
  18. History of psychotropic substance abuse with inability to abstain, or presence of a psychiatric disorder.
  19. Participation in another clinical trial involving antitumour agents within 4 weeks prior to enrolment.
  20. Prior or concurrent untreated malignancy, excluding cured basal cell carcinoma of the skin, cervical carcinoma in situ, or superficial bladder cancer.
  21. Use of medications or foods known to be potent cytochrome P450 3A4 (CYP3A4) inhibitors within 7 days prior to the first dose, including but not limited to: atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin, and voriconazole.
  22. Use of medications known to be potent CYP3A4 inducers within 12 days prior to the first dose, including but not limited to: carbamazepine, phenobarbital, phenytoin, rifabutin, and rifampicin.
  23. Any other condition that, in the investigator's judgement, may affect the conduct of the clinical study or interpretation of results.
  24. Virological tests during the screening period meeting any of the following criteria:

(1)Hepatitis B surface antigen (HBsAg)-positive with HBV DNA levels exceeding the ULN (2)Anti-hepatitis C virus (HCV) antibody-positive and HCV ribonucleic acid (RNA)-positive Human immunodeficiency virus (HIV)-positive

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Non randomizzato
  • Modello interventistico: Assegnazione sequenziale
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: The first dose level

The first dose level of apatinib combined with fixed-dose 5-day courses of irinotecan (50 mg/m²/dose infused IV 90 min) plus temozolomide (150 mg/m²/dose infused IV 90 min) for up to 8 courses.

In the Phase I stage, apatinib was administered using a 3+3 dose escalation design with three dose cohorts. The IT regimen was maintained at fixed doses, with patients receiving up to 8 cycles of chemotherapy. The recommended Phase II dose (RP2D) was determined from the Phase I dose-escalation phase.

In the Phase II stage, the study included an apatinib combination therapy phase and an apatinib maintenance therapy phase. During the combination therapy phase, apatinib was administered at the RP2D in combination with the IT regimen (at fixed doses) for up to 8 cycles. In the maintenance therapy phase, apatinib was administered orally as a single agent at the RP2D until disease progression or intolerable toxicity occurred.

Altri nomi:
  • Irinotecano
  • temozolomide
Sperimentale: The second dose level

The second dose level of apatinib combined with fixed-dose 5-day courses of irinotecan (50 mg/m²/dose infused IV 90 min) plus temozolomide (150 mg/m²/dose infused IV 90 min) for up to 8 courses.

In the Phase I stage, apatinib was administered using a 3+3 dose escalation design with three dose cohorts. The IT regimen was maintained at fixed doses, with patients receiving up to 8 cycles of chemotherapy. The recommended Phase II dose (RP2D) was determined from the Phase I dose-escalation phase.

In the Phase II stage, the study included an apatinib combination therapy phase and an apatinib maintenance therapy phase. During the combination therapy phase, apatinib was administered at the RP2D in combination with the IT regimen (at fixed doses) for up to 8 cycles. In the maintenance therapy phase, apatinib was administered orally as a single agent at the RP2D until disease progression or intolerable toxicity occurred.

Altri nomi:
  • Irinotecano
  • temozolomide
Sperimentale: The third dose level

The third dose level of apatinib combined with fixed-dose 5-day courses of irinotecan (50 mg/m²/dose infused IV 90 min) plus temozolomide (150 mg/m²/dose infused IV 90 min) for up to 8 courses.

In the Phase I stage, apatinib was administered using a 3+3 dose escalation design with three dose cohorts. The IT regimen was maintained at fixed doses, with patients receiving up to 8 cycles of chemotherapy. The recommended Phase II dose (RP2D) was determined from the Phase I dose-escalation phase.

In the Phase II stage, the study included an apatinib combination therapy phase and an apatinib maintenance therapy phase. During the combination therapy phase, apatinib was administered at the RP2D in combination with the IT regimen (at fixed doses) for up to 8 cycles. In the maintenance therapy phase, apatinib was administered orally as a single agent at the RP2D until disease progression or intolerable toxicity occurred.

Altri nomi:
  • Irinotecano
  • temozolomide
Sperimentale: Phase 2: The RPIID group

Based on the Phase I stage of apatinib, the recommended phase II dose was administered in combination with the IT regimen every three weeks for up to 8 cycles, followed by maintenance therapy with apatinib until tumor progression recurrence or unacceptable toxicity.

In the Phase I stage, apatinib was administered using a 3+3 dose escalation design with three dose cohorts. The IT regimen was maintained at fixed doses, with patients receiving up to 8 cycles of chemotherapy. The recommended Phase II dose (RP2D) was determined from the Phase I dose-escalation phase.

In the Phase II stage, the study included an apatinib combination therapy phase and an apatinib maintenance therapy phase. During the combination therapy phase, apatinib was administered at the RP2D in combination with the IT regimen (at fixed doses) for up to 8 cycles. In the maintenance therapy phase, apatinib was administered orally as a single agent at the RP2D until disease progression or intolerable toxicity occurred.

Altri nomi:
  • Irinotecano
  • temozolomide

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Best objective response rate (Phase 2)
Lasso di tempo: Up to 8 cycles of combination therapy (approximately 6 months)

Proportion of patients with a best overall response of complete response (CR) or partial response (PR) according to the revised International Neuroblastoma Response Criteria, assessed by the investigator in phase 2 patients treated at the recommended phase 2 dose (RP2D).

Up to 8 cycles of combination therapy (approximately 6 months)
Incidence of dose-limiting toxicity (Phase 1)
Lasso di tempo: First 21-day cycle after the first apatinib dose

Proportion of DLT-evaluable patients experiencing at least one dose-limiting toxicity during the first 21-day cycle, defined as grade ≥3 febrile neutropenia; grade 4 neutropenia persisting >7 days despite G-CSF; grade 4 thrombocytopenia or grade 3 thrombocytopenia with clinically significant bleeding; grade ≥4 anaemia; grade ≥3 non-haematological toxicity not resolving to grade ≤2 within 7 days despite optimal supportive care; or any adverse event requiring treatment interruption >7 days or dose reduction.

First 21-day cycle after the first apatinib dose
Maximum tolerated dose and recommended phase 2 dose (Phase 1)
Lasso di tempo: At completion of phase 1 dose escalation

Maximum tolerated dose (MTD) determined by the 3+3 dose-escalation design, and recommended phase 2 dose (RP2D) determined from an integrated review of dose-limiting toxicities, grade ≥3 adverse events, serious adverse events, dose interruptions and reductions, tolerability, treatment compliance and pharmacokinetic exposure.

At completion of phase 1 dose escalation

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Progression-free survival
Lasso di tempo: Up to 60 months

Time from enrollment to first documented disease progression or death from any cause, whichever occurs first.

Up to 60 months
Overall survival
Lasso di tempo: Up to 60 months

Time from enrollment to death from any cause.

Up to 60 months
duration of response(DOR)
Lasso di tempo: Up to 60 months

Time from the first documented confirmed complete or partial response to first documented disease progression or death from any cause, whichever occurs first, among responders.

Up to 60 months
Disease control rate (DCR)
Lasso di tempo: Up to 8 cycles of combination therapy (approximately 6 months)

Proportion of patients with a best overall response of complete response, partial response, minor response, or stable disease lasting at least 8 weeks.

Up to 8 cycles of combination therapy (approximately 6 months)
Time to response
Lasso di tempo: Up to 60 months

Time from the first study treatment to the first documented confirmed complete or partial response among responders.

Up to 60 months
Safety and tolerability
Lasso di tempo: From first dose until 30 days after the last dose (up to 60 months)

Incidence and severity of adverse events and serious adverse events, and the number and reason for dose interruptions and dose reductions, graded according to NCI-CTCAE version 5.0.

From first dose until 30 days after the last dose (up to 60 months)
Pharmacokinetic parameters of apatinib (Phase 1)
Lasso di tempo: First 48 hours after the first apatinib dose

Cmax, Tmax, AUC0-t, AUC0-inf, terminal half-life, mean residence time, clearance and apparent volume of distribution of apatinib after the first dose, analysed by non-compartmental methods.

First 48 hours after the first apatinib dose
Objective response rate (Phase 1)
Lasso di tempo: Up to 8 cycles of combination therapy (approximately 6 months)

Proportion of phase 1 patients achieving a complete or partial response.

Up to 8 cycles of combination therapy (approximately 6 months)

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Genomic biomarkers associated with antitumor activity (exploratory)
Lasso di tempo: Baseline tumour tissue; association analyses through data cutoff (up to 60 months)

Association between tumour genomic alterations, including pathway-level alteration frequencies and tumour mutational burden assessed by whole-exome sequencing of paired tumour and germline samples, and antitumor activity (objective response, disease control, progression-free survival and overall survival) in the biomarker-evaluable population.

Baseline tumour tissue; association analyses through data cutoff (up to 60 months)

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Yizhuo Zhang, Sun Yat-Sen University Cancer Center

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

26 agosto 2021

Completamento primario (Effettivo)

4 febbraio 2026

Completamento dello studio (Effettivo)

4 febbraio 2026

Date di iscrizione allo studio

Primo inviato

22 agosto 2021

Primo inviato che soddisfa i criteri di controllo qualità

24 agosto 2021

Primo Inserito (Effettivo)

30 agosto 2021

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

10 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

5 novembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi